Volume 28, Issue 149, July 2024

The effects of hemoperfusion on the recovery of COVID-19 patients: A pilot trial

Saman Farshid¹, Mohammadreza Doosti Rezaei¹, Khadijeh Makhdoomi¹, Behdad Broofeh¹, Mahdi Hemmati Ghavshough^2♦

¹Nephrology and Kidney Transplant Research Center, Clinical Research Institute, Urmia University of Medical Science, Urmia, Iran
²Department of Urology, Tabriz University of Medical Sciences, Faculty of Medicine, Tabriz, Iran

^♦Corresponding Author
Department of Urology, Tabriz University of Medical Sciences, Faculty of Medicine, Tabriz, Iran

ABSTRACT

Background: As a treatment method, considerable amounts of patients' blood are transferred to absorbents to remove blood cytokines in hemoperfusion. The present research studies the contribution of hemoperfusion to the outcomes observed in patients with COVID-19. Methods: The present quasi-experimental pilot trial recruited 80 patients hospitalized in intensive care units (ICU) suffering from COVID-19 who received hemoperfusion. Hemoperfusion was conducted for the patients in the study group in two 3-hour sessions. The requirement of respiratory support and mortality were estimated. Results: The patients were 56.37±14.97 years old on average. 92.5% of patients were polymerase chain reaction (PCR) positive, while the others showed the radiographic characteristic of COVID-19. In total, 52.5% of the patients died. The most prevalent clinical presentations were fever and cough. The average saturation of oxygen after and before conducting the hemoperfusion was 81.41±10.92 and 77.84±13.33, respectively. Most of those who died had an involvement higher than 75%. The reductions observed in the platelet and hemoglobin levels following hemoperfusion were recorded. In addition, urea and alanine aminotransferase (ALT) levels increased following the hemoperfusion. Conclusions: Hemoperfusion can result in decreased levels of platelet and hemoglobin and increased levels of urea and ALT, indicating the adverse effects of hemoperfusion on the COVID-19 patients receiving this treatment. The most important predictive factor determining the mortality rate of the COVID-19 patients receiving hemoperfusion was intubation.

Keywords: Coronavirus Disease 2019, SARS-CoV-2, Hemoperfusion, COVID-19, Pilot Study, Recovery

Medical Science, 2024, 28, e70ms3372

PDF

DOI: https://doi.org/10.54905/disssi.v28i149.e70ms3372

Published: 03 July 2024